New Insights on Mechlorethamine/Chlormethine gel presented at 4th World Congress of Cutaneous Lymphomas
February 14, 2020 08:00 ET
|
Helsinn Healthcare S.A.
New Insights on Mechlorethamine/Chlormethine gel presented at 4th World Congress of Cutaneous Lymphomas Lugano, Switzerland, February 14, 2020 – Helsinn, the Swiss pharmaceutical group focused on...
Lyfebulb and Helsinn Announce the Winners of the Third Annual Lyfebulb-Helsinn Cancer Innovation Summit & Award
January 31, 2020 02:30 ET
|
Helsinn Healthcare S.A.
Lyfebulb and Helsinn Announce the Winners of the Third Annual Lyfebulb-Helsinn Cancer Innovation Summit & Award MONACO, PRINCIPALITY OF MONACO, AND NEW YORK, NY, USA, January 31, 2020:...
Helsinn Group Grants Exclusive Licensing Rights to Berlin-Chemie AG, a company of the Menarini Group, for ONICIT®/ALOXI® and AKYNZEO® in Russia and CIS region
January 27, 2020 03:30 ET
|
Helsinn Healthcare S.A.
Helsinn Group Grants Exclusive Licensing Rights to Berlin-Chemie AG, a company of the Menarini Group, for ONICIT®/ALOXI® and AKYNZEO® in Russia and CIS region Berlin-Chemie AG has been granted...
Lyfebulb and Helsinn Announce 11 Finalists for the Third Annual Lyfebulb-Helsinn Cancer Innovation Summit & Award
January 14, 2020 08:00 ET
|
Helsinn Healthcare S.A.
Lyfebulb and Helsinn Announce 11 Finalists for the Third Annual Lyfebulb-Helsinn Cancer Innovation Summit & Award The Award recognizes Patient Entrepreneurs demonstrating outstanding...
Helsinn appoints Eric Cornut and Lonnie Moulder to the Board of Directors
January 13, 2020 06:36 ET
|
Helsinn Healthcare S.A.
Helsinn appoints Eric Cornut and Lonnie Moulder to the Board of Directors Lugano, Switzerland, January 13, 2020 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care...
Helsinn to present a scientific poster on acute care use following CINV prophylaxis with agents in breast cancer patients at the San Antonio Breast Cancer Symposium (SABCS) 2019
December 13, 2019 09:00 ET
|
Helsinn Healthcare S.A.
Lugano, Switzerland, December 13, 2019 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, is presenting a scientific poster assessing acute care involving...
Helsinn supported ‘70 Years of Cancer Care in China’ celebratory event in Shanghai
November 14, 2019 03:00 ET
|
Helsinn Healthcare S.A.
Helsinn supported ‘70 Years of Cancer Care in China’ celebratory event in Shanghai Lugano, Switzerland, November 14, 2019 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer...
Helsinn attends 4th Annual Sino-Swiss Business Awards
November 07, 2019 03:38 ET
|
Helsinn Healthcare S.A.
Helsinn attends 4th Annual Sino-Swiss Business Awards Lugano, Switzerland, November 7, 2019 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, attended the 4th...
Helsinn to co-host MF-CTCL satellite symposium alongside Recordati Rare Diseases at the EADV 2019 Congress GNW: European only
October 09, 2019 05:00 ET
|
Helsinn Healthcare S.A.
Helsinn to co-host alongside Recordati Rare Diseases satellite symposium on MF-CTCL diagnosis optimization at European Academy of Dermatology and Venereology Congress 2019 Lugano, Switzerland,...
Helsinn demonstrates commitment to MF CTCL with multiple scientific sessions at the EORTC Cutaneous Lymphoma Meeting 2019
September 26, 2019 08:54 ET
|
Helsinn Healthcare S.A.
Helsinn demonstrates commitment to MF CTCL with multiple scientific sessions at the EORTC Cutaneous Lymphoma Meeting 2019 Lugano, Switzerland, September 26, 2019 – Helsinn, the Swiss pharmaceutical...